SCHOLAR ROCK HOLDING CORPORATION Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $11.41M, a 249.66% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $5.42M, a 7.58% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $3.87M, a 1637.22% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $3.26M, a 6840.43% increase year-over-year.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for fiscal 2025 was $23.81M, a 25.49% increase from fiscal 2024.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for fiscal 2024 was $18.98M, a 1136.16% increase from fiscal 2023.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for fiscal 2023 was $1.53M, a 209.48% increase from fiscal 2022.
- SCHOLAR ROCK HOLDING CORPORATION stock issued during period, value, stock options exercised for fiscal 2022 was $496.00K, a 92.80% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $11.41M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $5.42M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $23.81M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $3.87M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $3.26M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $5.04M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $18.98M 10-K · filed 2026-03-03 | |
| 2024-09-30 | $223.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $47.00K 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $280.00K 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $1.53M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $280.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $292.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $243.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $496.00K 10-K · filed 2024-03-19 | |
| 2022-09-30 | $5.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $2.00K 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $481.00K 10-Q · filed 2023-11-07 | |
| 2021-12-31 | $6.89M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $1.97M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $611.00K 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $2.74M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $7.29M 10-K · filed 2022-03-07 | |
| 2020-09-30 | $374.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $598.00K 10-Q · filed 2021-11-09 | |
| 2020-03-31 | $405.00K 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $913.00K 10-K · filed 2021-03-09 | |
| 2019-06-30 | $79.00K 10-Q · filed 2020-11-09 | |
| 2019-03-31 | $13.00K 10-Q · filed 2020-11-09 | |
| 2018-12-31 | $6.00K 10-K · filed 2020-03-12 | |
| 2018-09-30 | $3.00K 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |